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Soluble erythropoietin receptor is present in the mouse brain and
is required for the ventilatory acclimatization to hypoxia
Abstract
While erythropoietin (Epo) and its receptor (EpoR) have been widely investigated in brain, the
expression and function of the soluble Epo receptor (sEpoR) remain unknown. Here we demonstrate
that sEpoR, a negative regulator of Epo's binding to the EpoR, is present in the mouse brain and is
down-regulated by 62% after exposure to normobaric chronic hypoxia (10% O2 for 3 days).
Furthermore, while normoxic minute ventilation increased by 58% in control mice following hypoxic
acclimatization, sEpoR infusion in brain during the hypoxic challenge efficiently reduced brain Epo
concentration and abolished the ventilatory acclimatization to hypoxia (VAH). These observations
imply that hypoxic downregulation of sEpoR is required for adequate ventilatory acclimatization to
hypoxia, thereby underlying the function of Epo as a key factor regulating oxygen delivery not only by
its classical activity on red blood cell production, but also by regulating ventilation.
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While erythropoietin (Epo) and its receptor (EpoR) have been widely investigated in brain,
the expression and function of the soluble Epo receptor (sEpoR) remain unknown. Here we
demonstrate that sEpoR, a negative regulator of Epo’s binding to the EpoR, is present in the
mouse brain and is down-regulated by 62% after exposure to normobaric chronic hypoxia (10%
O2 for 3 days). Furthermore, while normoxic minute ventilation increased by 58% in control
mice following hypoxic acclimatization, sEpoR infusion in brain during the hypoxic challenge
efficiently reduced brain Epo concentration and abolished the ventilatory acclimatization to
hypoxia (VAH). These observations imply that hypoxic downregulation of sEpoR is required for
adequate ventilatory acclimatization to hypoxia, thereby underlying the function of Epo as a key
factor regulating oxygen delivery not only by its classical activity on red blood cell production,
but also by regulating ventilation.
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Erythropoietin (Epo) is a pleiotropic cytokine most
commonly recognized as a factor that improves arterial
oxygen carrying capacity (Gassmann et al. 2003; Sasaki,
2003). Upon sustained hypoxaemic conditions Epo
synthesis in the kidney is accelerated, resulting in increased
plasma Epo levels (Eckardt & Kurtz, 2005; Stockmann
& Fandrey, 2006). Binding of Epo to its receptor
(EpoR) on erythrocyte progenitor cells in the bone
marrow maintains their viability, promotes cell division,
and increases haemoglobin synthesis culminating in
increased haematocrit levels (Fisher, 2003; Jelkmann,
2005). While this endocrine loop is essential, it is not
sufficient to ensure fast and adequate oxygen supply under
conditions of limited oxygen availability such as in high
altitude or in patients suffering from impaired respiratory
functions. Sustained hypoxic exposure also affects the
respiratory control network, leading to a progressive,
species-dependent increase in minute ventilation over
minutes, hours or even weeks. This process is defined
as the ventilatory acclimatization to hypoxia (VAH) and
persists for a few days following return to normoxic
M. Gassmann and V. Joseph contributed equally to this work.
conditions. VAH mainly relies on increased sensitivity
of peripheral chemoreceptors to hypoxia, associated with
central facilitation of the ventilatory output (Forster et al.
1981; Dempsey & Forster, 1982; Smith et al. 1986; Powell
et al. 2000a; Prabhakar & Jacono, 2005). Here we show that
the soluble form of EpoR (sEpoR) is involved in the VAH.
Endogenous expression of Epo has been reported in the
nervous system (Digicaylioglu et al. 1995; Gassmann et al.
2003) and transgenic mice overexpressing human Epo in
neural cells have shown that brain-derived Epo facilitates
VAH (Soliz et al. 2005). Furthermore it was reported that
the EpoR is present in respiratory areas of the brain-
stem, such as NK-1R positive neurons in the pre-Bo¨tzinger
complex (proposed as the respiratory rhythm generator),
and the nucleus tractus solitarii, which relays input from
peripheral chemoreceptors to the central respiratory areas
to increase ventilation upon hypoxic exposure (Soliz et al.
2005). In analogy to several other members of the cytokine
superfamily type I transmembrane proteins, EpoR is also
synthesized in a soluble form (sEpoR) that corresponds to
the extracellular domain of the complete receptor (Nagao
et al. 1992; Harris & Winkelmann, 1996; Westphal et al.
2002). Synthesis of the sEpoR occurs by alternative splicing
of EpoR mRNA. Following secretion into the extracellular
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fluid, sEpoR binds Epo, thereby limiting its ability to bind
EpoR (Kuramochi et al. 1990; Baynes et al. 1993). While
the presence of sEpoR has been reported in plasma and
several tissues including liver, spleen, kidney, heart and
bone marrow (Fujita et al. 1997), its cerebral expression
and function has not been investigated yet. In the present
work we show that sEpoR is expressed in the mouse brain.
Moreover, down-regulation of sEpoR upon exposure to




A total of 20 adult male C57/Bl6 mice (Charles River
Canada) at the age of 3 months were housed for 1 week
at constant temperature (21 ± 1◦C) and light (from 07.00
to 19.00 h). Brain tissue and blood were collected from 10
mice to measure cerebral and plasma Epo before (n = 5)
and after (n = 5) VAH, as described below. The other 10
animals were used to measure ventilation in normoxia and
acute hypoxia, before and after being surgically connected
to a cannula (see below) and exposed to 10% O2 for 3 days.
A whole-body flow-though plethysmography (EMKA
Technologies, France) was used to monitor ventilation as
described (Soliz et al. 2005). Briefly, mice were placed
in a 600 ml chamber continuously supplied with air-
flow at 0.7–0.8 l min−1 using flow restrictors. Ventilation
(V˙E) was calculated as the product of tidal volume (V T)
and respiratory frequency (f R) and normalized to 100 g
of body weight (e.g. ml min−1 (100 g)−1). Ventilatory
measurements were performed in normoxia (21% O2).
Acute hypoxia was achieved by flushing air balanced in
N2. The fraction of inspired O2 (FIO2 ) in the chamber was
gradually decreased from 21% to 10% O2 during 15 min.
Respiratory recordings at 10% O2 were performed for
20 min. At the end of each experiment, body weight and
body temperature (rectal thermocouple, Physitemp, USA)
were measured. In parallel to ventilation measurements,
O2 consumption (V˙O2 , ml min−1 (100 g)−1) and CO2
production (V˙CO2 , ml min−1 (100 g)−1) were determined
by O2 and CO2 analysers (AEI technologies). Ventilatory
measurements were performed under similar conditions
before and after chronic hypoxic exposure. All animal
procedures have been approved by the ethics committee of
animal care at Laval University and followed the guidelines
of the Canadian Council on Animal Care.
Intracerebroventricular infusions
For intracerebroventricular infusion, the animals were
deeply anaesthetized with a gas mixture of 4% halothane,
70% N2 and O2, and maintained by reducing the
inspired halothane concentration to 1–1.5%. Body
temperature of the mice was maintained at 37◦C using
a temperature-controlled heating pad. They were then
stereotaxically implanted with a permanent stainless-steel
cannula (Alzet, Durect Corp., Toronto, Canada) into the
left lateral ventricle of the brain at coordinates (Bregma:
0; L: 1 mm, and DV: −3 mm) according to Paxinos
and Watson (Paxinos & Watson 2000). Subsequently an
osmotic minipump (Alzet pump model 1003D; 100 μl;
flow rate 1.4 μl h−1; Durect Corp.) was connected to the
cannula with medical grade vinyl tubing and placed in a
s.c. pocket in the dorsal region. Pumps were filled with
soluble EpoR solution (50 μg; R & D systems, Inc., USA)
or vehicle (phosphate buffer). After surgery, mice were
allowed to recover in isolation and observed for at least 1 h
until complete recovery from anaesthesia.
Quantification of Epo, EpoR and sEpoR
Mice were anaesthetized by an intraperitoneal injection
of a mixture of ketamine (80 mg kg−1) and xylazine
(10 mg kg−1). Blood samples were drawn by cardiac
puncture into heparinized Ependorff tubes and plasma was
collected after samples centrifugation at (18 000 g) Brain
samples were obtained after transcardial perfusion of mice
with phosphate buffer (0.1 m, pH 7.4) and immediately
frozen in liquid nitrogen. For the extraction of total
protein, brain tissues were complemented with lysis
buffer, homogenized and centrifuged, and supernatants
were harvested. Protein concentrations of both brain and
plasma were determined by the Bradford protein assay
(Bio-Rad, Hercules, CA, USA). Epo levels in brain and
plasma were quantified using an 125I-Epo-based radio-
immunoassay (RIA) (Amersham, Zurich, Switzerland),
according to previously published protocols (Kilic et al.
2005). The lower detection limit of our RIA was 4 U l−1,
and the intrassay/interassay variances were < 2% and
< 6%, respectively. For quantification of EpoR and sEpoR
in brain samples, equal amounts of extracts were separated
by 10% SDS-PAGE and transferred onto a nitrocellulose
membrane. Transfer and equal loading of proteins were
confirmed by Ponceau S staining. For immunoblotting,
the membranes were incubated with an EpoR antibody
(H-194, Santa Cruz Biotechnology Inc., Lab Force
G CH-4208, Nummingen, Switzerland; 1 : 200) and
with the appropriate horseradish peroxidase-conjugated
secondary antibody. EpoR and sEpoR were detected at the
expected molecular weight (64 and 30 kDa, respectively;
Nagao et al. 1992) by enhanced chemiluminescence
and quantified using a Gel Doc 2000 scanner with
Quantity One software (Bio-Rad). The membrane was
then stripped (10 ml stripping buffer complemented
with 70 μl β-mercaptoethanol) for 20 min and incubated
with monoclonal anti-β-actin primary antibody (AC-15,
Sigma, USA; 1 : 5000), followed by suitable secondary
antibody. The intensity of the Epo and sEpoR bands was
then normalized to actin.
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Statistical analysis
Analysis was performed using the StatView software
(Abacus Concepts, Berkeley, CA, USA). The reported
values are means ± s.d. For simple measurements, data
were analysed by one-way ANOVA. For hypoxic ventilation
responses, data were analysed by two-way ANOVA for
repeated measurements. Differences were considered
significant at P < 0.05.
Results
sEpoR is endogenously expressed in brain and is
down-regulated upon chronic exposure to hypoxia
We performed Western blot and RIA analysis on mouse
brain extracts. Both EpoR and sEpoR were detected
under normoxia and after 3 days of hypoxic exposure
(10% O2; Fig. 1). While the levels of EpoR (Fig. 1A) and
Epo (Fig. 1C) synthesized in the hypoxic brain were not
significantly altered compared to the normoxic control,
hypoxia reduced the expression of sEpoR in the brain
by 62% (Fig. 1B). Exposure to chronic hypoxia increased
plasma Epo in mice (54%; Fig. 1D), confirming that the
animals were indeed hypoxaemic. These data demonstrate
that sEpoR is endogenously expressed in the mouse
brain and that its expression is down-regulated during
hypoxia.
Intracerebroventricular infusion of sEpoR blocks the
ventilatory acclimatization to hypoxia
Considering that mice achieve VAH within 3 days (Olson
& Saunders, 1987; Malik et al. 2005), we hypothesized
that the observed decrease in sEpoR expression in chronic
hypoxia enhances the ability of Epo to facilitate VAH.
We tested this hypothesis by performing respiratory
measurements in normoxia and also acute hypoxia (10%
O2) before and after acclimatization to chronic hypoxia
(10% O2 for 3 days; Fig. 2A). Minute ventilation (V˙E),
respiratory frequency (f R) and tidal volume (V T), as well as
metabolic variables and rectal temperature were evaluated
in 10 adult male mice before acclimatization. During the
following 3 days mice received intracranial infusion of
sEpoR (0.7 μg of sEpoR per hour over 3 days, n = 5)
and were compared to vehicle-treated controls (n = 5).
During the treatment animals were exposed to normobaric
chronic hypoxia (10% O2) and then returned to room air
for a second evaluation of ventilation under normoxic
and acute hypoxic conditions. No differences were
found between vehicle and sEpoR treated groups before
acclimatization (Fig. 2B–G, normoxia before treatment).
However, while control mice showed a large increase in
normoxic ventilation after chronic exposure to hypoxia,
this ventilatory acclimatization was completely blocked
by sEpoR infusion (Fig. 2B–F). As metabolic rate was
also increased following hypoxic exposure in control
mice (but not in sEpoR-treated animals), we corrected
ventilation to metabolic rate. We observed that chronic
hypoxia-mediated hyperventilation (higher V˙E
/
V˙O2 –
Fig. 2F) was blunted by the sEpoR infusion. This is
consistent with previous findings (Soliz et al. 2005)
showing that Epo’s effect on the ventilatory response to
hypoxia is neither due to altered body metabolism (Fig. 2E)
nor to alterations in body temperature (Fig. 2G).
The acute hypoxic ventilatory response upon VAH is
blunted in mice treated with sEpoR
As ventilatory acclimatization to hypoxia is also manifested
by an augmented response to subsequent acute hypo-
xia (Powell et al. 2000b; Malik et al. 2005; Soliz et al.
2005), acute hypoxic ventilation before and after the
acclimatization period was compared (Fig. 3). In control
mice acute hypoxic ventilation was doubled whereas in
sEpoR treated mice it was completely abolished (Fig. 3A),
due to increased tidal volume (V T; Fig. 3C) rather than
respiratory frequency (f R; Fig. 3B) after acclimatization.
These data demonstrate that sEpoR efficiently antagonizes
Figure 1. sEpoR is expressed in the mouse brain and is
down-regulated upon hypoxic exposure
Brain tissue and plasma were collected from mice kept at normoxia
(Nx; n = 5) and after 3 days of continuous exposure to hypoxia at
10% O2 (Hx; n = 5). EpoR and sEpoR were detected in the normoxic
(Nx) and hypoxic (Hx) brain (A and B). Note that Hx but not Nx reduced
the expression of sEpoR (B). The level of brain-derived Epo did not
increase after Hx (C), while plasma Epo was increased after hypoxic
stimulus as expected (D). Western blot analysis is exemplified at the
top of A and B, including the negative control (no primary antibody).
∗∗P < 0.01, ∗∗∗P < 0.001.
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Epo’s ventilatory effect in brain. In agreement with the
model of VAH proposed by Powell (Fig. 3D), control mice
gradually increased minute ventilation from normoxia
to acute hypoxia before acclimatization, and from
hypoxia before acclimatization to acute hypoxia after
acclimatization. In contrast, this effect was inhibited in
sEpoR-infused animals (Fig. 3E). A similar response was
observed in the oxygen convection ratio (Fig. 3F). Once
again, these alterations were not caused by differences
in body temperature after acclimatization (vehicle versus
sEpoR in Nx: 37.2 ± 0.4 to 37.7 ± 0.7◦C; in Hx: 35.9 ± 0.5
to 36.3 ± 0.4◦C).
Figure 2. Intracerebroventricular infusion of sEpoR abolishes VAH
A, schematic diagram showing the sequential steps of the experiment protocol. Normoxic (Nx) and acute hypoxic
(acute Hx) minute ventilation was evaluated before and after VAH (shaded area) in mice receiving continuous
intracerebroventricular infusion of sEpoR or vehicle. Before and after acclimatization, mice were kept at normoxic
conditions and the minute ventilation was determined. After acclimatization, control mice showed a large increase
of normoxic ventilation (V˙E), respiratory frequency (fR), tidal volume (VT) and oxygen consumption (V˙O2 ). In contrast,
this elevation in ventilation was abolished in the sEpoR group, showing that no acclimatization occurred (B, C, D
and E). Accordingly, the oxygen convection ratio (V˙E/V˙O2 ) increased progressively in the control mice group but
remained unaltered in sEpoR animals (F). These differences were not caused by altered body temperature (G).
∗∗∗P < 0.001.
Intracerebroventricular infusion of sEpoR
down-regulates the expression of cerebral Epo
and EpoR
Following the ventilatory measurements described above,
brain and plasma were collected to quantify Epo (by
RIA) as well as EpoR and sEpoR (by Western blot).
Treatment with sEpoR dramatically reduced the amount
of detectable EpoR and Epo (Fig. 4A and C). The level
of sEpoR did not increase (Fig. 4B) probably due to the
rapid metabolism of exogenous sEpoR or because the
resulting Epo–sEpoR complex was undetectable by either
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
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the Epo or EpoR antibody. Mice treated with sEpoR during
chronic hypoxic exposure had higher levels of plasma
Epo (Fig. 4D), a consistent sign of impaired VAH. These
results imply that reduced brain-derived Epo availability,
as induced by sEpoR infusion during chronic hypoxia,
abolishes the progressive augmentation of ventilation, thus
compromising the physiological acclimatization process to
hypoxia.
Figure 3. Exogenous application of sEpoR abolishes subsequent augmentation of acute hypoxic
ventilation induced by VAH
Acute hypoxic (acute Hx) ventilation was evaluated before and after VAH in mice infused with sEpoR or vehicle
(A, B and C). In line with Powell (D), the VAH is observed in vehicle-infused mice as a supplemental increase of
respiratory parameters measured in acute hypoxia after acclimatization (Hx after) compared to acute hypoxia before
(Hx before) acclimatization (E). Soluble EpoR administration abolished this process (A, B, C and E). The oxygen
convection ratio (V˙E/V˙O2 ) follows a similar dynamic (F). The 15 min gradual reduction of F IO2 from normoxia to
acute hypoxia is represented by the black triangles. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Discusion
Our results demonstrated for the first time that
endogenously synthesized Epo and sEpoR in the central
nervous system play a crucial role in the physiological
process related to long-term oxygen homeostasis, thereby
ultimately contributing to the same goal as plasma Epo,
i.e. increasing the overall capacity of oxygen delivery. This
finding is in agreement with previous data obtained in
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
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Figure 4. Intracerebroventricular infusion of sEpoR decreases
the levels of Epo and EpoR in the brain upon VAH
Brain tissue and plasma were collected from mice infused with sEpoR
or vehicle after VAH (3 days; 10% O2). Epo in brain and blood was
analysed by RIA and EpoR variants were determined by Western blot.
Western blot analysis is exemplified at the top of A and B, including
the negative control (no primary antibody). Compared to the untreated
control, the level of EpoR and Epo were decreased (A and C), while
sEpoR (B) did not alter in sEpoR-infused mice. Plasma Epo was higher
in the sEpoR group compared to control (D). ∗P < 0.01, ∗∗P < 0.001.
genetically modified mice overexpressing Epo in the brain,
in which the hypoxic ventilatory response persists after
carotid body denervation (Soliz et al. 2005). Our data
provide convincing evidence that the regulation of Epo and
sEpoR in the central nervous system and at a systemic level
is finely tuned to establish a balance between ventilatory
and haematopoietic control of oxygen carrying capacity as
shown by the proposed model for hypoxic acclimatization
presented in Fig. 5. Acute hypoxia triggers during the
Figure 5. Model of ventilatory acclimatization to
hypoxia (VAH) showing the contribution of cerebral
and plasma Epo
During the first minutes of hypoxia, carotid bodies sense
the drop of arterial oxygen pressure thus leading the
short-term response to hypoxia by promoting a fast
increase of ventilation. Persisting hypoxia activates
long-term regulation mechanisms. In mice, Epo synthesis
in brain and kidney is initiated a few hours after hypoxic
exposure. Plasma Epo augments the oxygen carrying
capacity (by gradual increase of the haematocrit) as well
as contributes to the regulation of ventilation (binding of
the EpoR present in the carotid body glomus cells). While
we recently showed that catecholamines are involved in
central regulation of ventilation, other molecules such as
nitric oxide and neuroglobin might be involved, too.
first minutes the response of the chemoreflex loop that
leads to an immediate increase in ventilation termed
hypoxic ventilatory response (short-term regulation).
If hypoxia persists, the organism enters a process of
acclimatization in which long-term regulatory responses
are initiated. Thereby, central and systemic availability
of Epo is increased. In mice, hypoxic induction of Epo
mRNA expression in the kidneys is maximal after 2 h,
while plasma Epo protein level peaks after 20 h, and despite
continuous hypoxia both mRNA and protein are quickly
lowered (Abbrecht & Littell, 1972; Chikuma et al. 2000).
Most probably, the elevated Epo concentration in the
blood immediately impacts the carotid bodies thereby
contributing to the modulation of ventilation. Note that we
recently showed a dense staining of EpoR in glomus cells
(Soliz et al. 2005). At the same time, increased Epo plasma
levels progressively augments the number of circulating
red cells to augment the oxygen carrying capacity. In
brain, the Epo mRNA reaches a peak expression after 4 h
of hypoxia. Additionally, we observed that brain-derived
Epo protein levels peaks after 24 h (unpublished data)
and then decreased to basal level after 72 h, this kinetic
being consistent with the HIF-1 expression in the hypo-
xic brain (Stroka et al. 2001). However, during the decay
of brain Epo, sEpoR expression is decreased to maintain
continuously high Epo availability. The mechanism by
which cerebral Epo controls VAH remains to be elucidated.
We previously showed that Epo regulates breathing by
altering catecholaminergic metabolism in the brain-
stem (Soliz et al. 2005). However we do not exclude
the involvement of other factors, such as nitric oxide
(Lipton et al. 2001) and neuroglobin (Hundahl et al.
2005), both up-regulated in brain after hypoxic induction
(Fig. 5).
On the other hand, although the mechanism involved
are not completely understood, it has been well established
that hypoxia causes changes in body metabolism (Gautier,
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
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1996). As such, acute hypoxia induces a decrease in oxygen
demand and an increase of ventilation mediated by an
augmented chemosensitive drive (Kline et al. 1998; Kline
et al. 2000; Kline et al. 2002). In parallel, VAH reestablishes
tissue oxygenation by offsetting minute ventilation to a
new basal level. Furthermore, we and others reported in
previous studies that the metabolic rate is increased after
VAH (Malik et al. 2005; Soliz et al. 2005), but the identity
of this event is unknown so far. At present, we cannot
explain why metabolic rate was not increased in sEpoR
infused mice. We speculate that the metabolic cost of
elevated minute ventilation, as seen in control mice, is not
occurring in sEpoR-treated animals due to their unaltered
ventilation. In line with this, we hypothesize that high Epo
plasma levels reflect a hypoxaemia that in turn hinders
higher metabolic rate.
Our data suggest that cerebral expression of Epo and/or
sEpoR in brain is implicated in respiratory disorders
occurring at high altitude such as acute and chronic
mountain sickness (Leon-Velarde et al. 1998; Joseph
et al. 2000; Joseph et al. 2002). Similarly, it is tempting
to speculate that this system could also play a role
in the respiratory plasticity induced by exposure to
intermittent hypoxia, either in adults or in newborn
mammals. Therefore, expression and regulation of
cerebral Epo and sEpoR are of central importance in the
physiological response to hypoxia providing new insights
into disease pathogenesis and to generate novel therapeutic
approaches.
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